Royalty Financing Dealmaking in Biopharma Industry Analyzed by CurrentPartnering

11 May 2012 • by Natalie Aster

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

The new report “Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition” by CurrentPartnering provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Report Details:

Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Published: May, 2012
Pages: 263
Price: US$ 2.695,00


Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
Revenue assets – also known as ‘synthetic royalties’, where a specialist investment company acquires the rights to a proportion of future revenue streams in return for a lump sum payment to the company

This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2007.

This report contains links to online copies of actual royalty financing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

More information can be found in the report “Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition” by CurrentPartnering.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com